Document is current
Any future updates will be listed below
-
Authors
Zhou, Chenfei
Wang, Bin
Teng, Christina
Yang, Hui
Piha-Paul, Sarina A.
Richardson, Gary
Malalasekera, Ashanya
Sun, Yajun
Wang, Wei
Liu, Jieqiong
Shi, Yan
Zhan, Xianbao
Lemech, Charlotte https://orcid.org/0000-0002-5399-9431
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04450732 at ClinicalTrials.govDocuments that mention this clinical trial
A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
https://doi.org/10.1186/s12967-024-05985-z
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 13 December 2024
First Online: 9 January 2025
Declarations
:
: All procedures conducted in studies involving human participants were aligned with the ethical standards of the institutional and/or national research committee, as well as with the Helsinki Declaration and its subsequent amendments, or with similar ethical standards. The study is registered with ClinicalTrials.gov (NCT 04450732).
: Not applicable.
: Sun YJ is an employee of GeneQuantum Healthcare (Suzhou) Co.,Ltd. No disclosures were reported by the other others.
